23 Dec 2023 • The ASPREE trial explored the impact of daily low-dose aspirin (oral 100 mg daily) on incident Type 2 Diabetes among older adults.

• Over a nearly 5-year period, the aspirin group exhibited a 15% reduction in the risk of developing diabetes & a slower increase in fasting plasma glucose levels.
• These benefits came with a caveat, as the aspirin group experienced a higher risk of major bleeding, including GI & intracranial bleeding.

Given the increasing prevalence of type 2 diabetes among older adults, the potential for anti-inflammatory agents such as aspirin to prevent type 2 diabetes or improve glucose levels warrants further study with a comprehensive assessment of all potential safety events of interest.

Source: The Lancet | Read full story